These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 9593014)

  • 1. Antibody persistence following preexposure regimens of cell-culture rabies vaccines: 10-year follow-up and proposal for a new booster policy.
    Strady A; Lang J; Lienard M; Blondeau C; Jaussaud R; Plotkin SA
    J Infect Dis; 1998 May; 177(5):1290-5. PubMed ID: 9593014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A serum-free, purified vero cell rabies vaccine is safe and as immunogenic as the reference vaccine Verorab for pre-exposure use in healthy adults: results from a randomized controlled phase-II trial.
    Pichon S; Guinet-Morlot F; Minutello M; Donazzolo Y; Rouzier R; Chassard D; Fitoussi S; Hou V
    Vaccine; 2013 Apr; 31(18):2295-301. PubMed ID: 23510665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serologic response to rabies pre-exposure vaccination in persons with potential occupational exposure in Singapore.
    Lim PL; Barkham TM
    Int J Infect Dis; 2010 Jun; 14(6):e511-3. PubMed ID: 20018545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety in adults of a new chromatographically purified Vero-cell rabies vaccine (CPRV): a randomized, double-blind trial with purified Vero-cell rabies vaccine (PVRV).
    Lang J; Cetre JC; Picot N; Lanta M; Briantais P; Vital S; Le Mener V; Lutsch C; Rotivel Y
    Biologicals; 1998 Dec; 26(4):299-308. PubMed ID: 10403033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pre-exposure rabies immunization in occupational exposed milieu. A 5-year prospective and comparative study of immunogenicity].
    Strady A; Lienard M; Ajjan N
    Presse Med; 1993 Apr; 22(12):572-6. PubMed ID: 8511091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistence of antibodies in children after intradermal or intramuscular administration of preexposure primary and booster immunizations with purified Vero cell rabies vaccine.
    Sabchareon A; Chantavanich P; Pasuralertsakul S; Pojjaroen-Anant C; Prarinyanupharb V; Attanath P; Singhasivanon V; Buppodom W; Lang J
    Pediatr Infect Dis J; 1998 Nov; 17(11):1001-7. PubMed ID: 9849982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the safety, immunogenicity, and pharmacokinetic profile of a new, highly purified, heat-treated equine rabies immunoglobulin, administered either alone or in association with a purified, Vero-cell rabies vaccine.
    Lang J; Attanath P; Quiambao B; Singhasivanon V; Chanthavanich P; Montalban C; Lutsch C; Pepin-Covatta S; Le Mener V; Miranda M; Sabchareon A
    Acta Trop; 1998 Jul; 70(3):317-33. PubMed ID: 9777717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rabies antibody seroprotection rates among travelers in Nepal: "rabies seroprotection in travelers".
    Ranney M; Partridge R; Jay GD; Rozzoli DE; Pandey P
    J Travel Med; 2006; 13(6):329-33. PubMed ID: 17107424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early rabies antibody response to intramuscular booster in previously intradermally immunized travelers using human diploid cell rabies vaccine.
    Gherardin AW; Scrimgeour DJ; Lau SC; Phillips MA; Kass RB
    J Travel Med; 2001; 8(3):122-6. PubMed ID: 11468113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of PVRV and HDCV rabies vaccines as to immunity, reliability and protective value].
    Hacibektaşoğlu A; Inal A; Eyigün C; Barut A; Türkay FA
    Mikrobiyol Bul; 1992 Jan; 26(1):26-36. PubMed ID: 1574019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rabies neutralizing antibody after 2 intradermal doses on days 0 and 21 for pre-exposure prophylaxis.
    Wongsaroj P; Udomchaisakul P; Tepsumethanon S; Khawplod P; Tantawichien T
    Vaccine; 2013 Mar; 31(13):1748-51. PubMed ID: 23370149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence of rabies antibody 5 years after postexposure prophylaxis with vero cell antirabies vaccine and antibody response to a single booster dose.
    Zhang X; Zhu Z; Wang C
    Clin Vaccine Immunol; 2011 Sep; 18(9):1477-9. PubMed ID: 21752947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized open-labeled study to demonstrate the non-inferiority of purified chick-embryo cell rabies vaccine administered in the Zagreb regimen (2-1-1) compared with the Essen regimen in Chinese adults.
    Ma J; Wang H; Li J; Chang L; Xie Y; Liu Z; Zhao Y; Malerczyk C
    Hum Vaccin Immunother; 2014; 10(10):2805-12. PubMed ID: 25483635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of a new chromatographically purified rabies vaccine in comparison to the human diploid cell vaccine.
    Arora A; Moeller L; Froeschle J
    J Travel Med; 2004; 11(4):195-9. PubMed ID: 15541220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody response after a two-year intradermal booster of rabies human diploid cell vaccine.
    Horman JT; Rullán JV; Myers RA; Bond JO; Israel E; Joseph JM
    J Am Vet Med Assoc; 1987 Jul; 191(2):185-7. PubMed ID: 3610792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of a serum-free purified Vero rabies vaccine in healthy adults: A randomised phase II pre-exposure prophylaxis study.
    Pichon S; Moureau A; Petit C; Chu L; Essink B; Muse D; Saleh J; Guinet-Morlot F; Minutello AM
    Vaccine; 2022 Aug; 40(33):4780-4787. PubMed ID: 35778281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One-year immunogenicity kinetics and safety of a purified chick embryo cell rabies vaccine and an inactivated Vero cell-derived Japanese encephalitis vaccine administered concomitantly according to a new, 1-week, accelerated primary series.
    Cramer JP; Jelinek T; Paulke-Korinek M; Reisinger EC; Dieckmann S; Alberer M; Bühler S; Bosse D; Meyer S; Fragapane E; Costantini M; Pellegrini M; Lattanzi M; Dovali C
    J Travel Med; 2016 Mar; 23(3):. PubMed ID: 26994987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preexposure immunization with intradermal human diploid cell rabies vaccine. Risks and benefits of primary and booster vaccination.
    Bernard KW; Mallonee J; Wright JC; Reid FL; Makintubee S; Parker RA; Dwyer DM; Winkler WG
    JAMA; 1987 Feb; 257(8):1059-63. PubMed ID: 3806894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of purified vero cell rabies vaccine used in the treatment of fox-bite victims in India.
    Matha IS; Salunke SR
    Clin Infect Dis; 2005 Feb; 40(4):611-3. PubMed ID: 15712086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody Response Following Pre-Exposure Immunization Against Rabies in High-Risk Professionals.
    Dougas G; Mavrouli M; Vrioni G; Lytras T; Mellou K; Metallidis S; Istikoglou I; Mitrou K; Tzani M; Georgopoulou I; Tsalikoglou F; Garetsou E; Poulakou G; Giannitsioti E; Moschopoulos C; Baka A; Georgakopoulou T; Tsiodras S; Tsakris A
    Vector Borne Zoonotic Dis; 2020 Apr; 20(4):303-309. PubMed ID: 31794689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.